E. C. Gil

发表

Update on adjuvant hormonal treatment of early breast cancer

R. Martínez, J. Romera, Teresa Hernández, 2011 .

Biomarker Analyses in the Phase 3 ASCENT Study of Sacituzumab Govitecan Versus Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer.

L. Carey, A. Bardia, H. Rugo, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Defining the optimal sequence for the systemic treatment of metastatic breast cancer

P. Auñón, P. Sánchez‐Rovira, J. A. Mestres, 2016, Clinical and Translational Oncology.

Characterization of plasma circulating small extracellular vesicles in patients with metastatic solid tumors and newly diagnosed brain metastasis

G. De Velasco, D. Castellano, H. Peinado, 2021, bioRxiv.

Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer

Eva Maria Ciruelos Gil, E. C. Gil, 2014 .

Abstract PD01-01: Cetuximab + Cisplatin in Estrogen Receptor-Negative, Progesterone Receptor-Negative, HER2-Negative (Triple-Negative) Metastatic Breast Cancer: Results of the Randomized Phase II BALI-1 Trial

A. Schneeweiss, J. Baselga, A. Zubel, 2010 .

Abstract PS11-05: Updated data from SERENA-1: A Phase 1 dose escalation and expansion study of the next generation oral SERD AZD9833 as a monotherapy and in combination with palbociclib, in women with ER-positive, HER2-negative advanced breast cancer

A. Cohen, U. Banerji, P. Kabos, 2021 .

Abstract GS3-06: Biomarker evaluation in the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer

L. Carey, A. Bardia, H. Rugo, 2021 .

Prospective, multicenter study on the economic and clinical impact of gene-expression assays in early-stage breast cancer from a single region: the PREGECAM registry experience

M. Martín, J. García-Saenz, J. A. Guerra Martínez, 2019, Clinical and Translational Oncology.

Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer

Shaughnessy, O. J., L. Carey, 2022 .

Oral vinorelbine (NVBO) in combination with trastuzumab (HER) in metastatic breast cancer (MBC): Data on efficacy and safety when administered in first- or second-line treatment.

F. Carabantes, J. Illarramendi, E. C. Gil, 2010 .